Novel Association of the NOTCH Pathway Regulator MIB1 Gene With the Development of Bicuspid Aortic Valve.


Journal

JAMA cardiology
ISSN: 2380-6591
Titre abrégé: JAMA Cardiol
Pays: United States
ID NLM: 101676033

Informations de publication

Date de publication:
01 08 2023
Historique:
pmc-release: 01 02 2024
medline: 10 8 2023
pubmed: 5 7 2023
entrez: 5 7 2023
Statut: ppublish

Résumé

Nonsyndromic bicuspid aortic valve (nsBAV) is the most common congenital heart valve malformation. BAV has a heritable component, yet only a few causative genes have been identified; understanding BAV genetics is a key point in developing personalized medicine. To identify a new gene for nsBAV. This was a comprehensive, multicenter, genetic association study based on candidate gene prioritization in a familial cohort followed by rare and common association studies in replication cohorts. Further validation was done using in vivo mice models. Study data were analyzed from October 2019 to October 2022. Three cohorts of patients with BAV were included in the study: (1) the discovery cohort was a large cohort of inherited cases from 29 pedigrees of French and Israeli origin; (2) the replication cohort 1 for rare variants included unrelated sporadic cases from various European ancestries; and (3) replication cohort 2 was a second validation cohort for common variants in unrelated sporadic cases from Europe and the US. To identify a candidate gene for nsBAV through analysis of familial cases exome sequencing and gene prioritization tools. Replication cohort 1 was searched for rare and predicted deleterious variants and genetic association. Replication cohort 2 was used to investigate the association of common variants with BAV. A total of 938 patients with BAV were included in this study: 69 (7.4%) in the discovery cohort, 417 (44.5%) in replication cohort 1, and 452 (48.2%) in replication cohort 2. A novel human nsBAV gene, MINDBOMB1 homologue MIB1, was identified. MINDBOMB1 homologue (MIB1) is an E3-ubiquitin ligase essential for NOTCH-signal activation during heart development. In approximately 2% of nsBAV index cases from the discovery and replication 1 cohorts, rare MIB1 variants were detected, predicted to be damaging, and were significantly enriched compared with population-based controls (2% cases vs 0.9% controls; P = .03). In replication cohort 2, MIB1 risk haplotypes significantly associated with nsBAV were identified (permutation test, 1000 repeats; P = .02). Two genetically modified mice models carrying Mib1 variants identified in our cohort showed BAV on a NOTCH1-sensitized genetic background. This genetic association study identified the MIB1 gene as associated with nsBAV. This underscores the crucial role of the NOTCH pathway in the pathophysiology of BAV and its potential as a target for future diagnostic and therapeutic intervention.

Identifiants

pubmed: 37405741
pii: 2806407
doi: 10.1001/jamacardio.2023.1469
pmc: PMC10323766
mid: NIHMS1915245
doi:

Substances chimiques

Receptors, Notch 0
MIB1 ligase, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

721-731

Subventions

Organisme : NCI NIH HHS
ID : R35 CA220340
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL150401
Pays : United States
Organisme : NHLBI NIH HHS
ID : R21 HL150373
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL114823
Pays : United States

Auteurs

Idit Tessler (I)

Cardiology Department, Hadassah Medical Center, Jerusalem, Israel.
Sheba Medical Center, Ramat Gan, Israel.
Faculty of Medicine, the Hebrew University, Jerusalem, Israel.
Braun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Juliette Albuisson (J)

Genetics Department, Assistance Publique-Hȏpitaux de Paris, Hôpital Européen Georges Pompidou, National Referral Center for Rare Vascular Diseases, VASCERN MSA European Reference Center, Paris, France.
Université Paris Cité, INSERM, U970 PARCC, Paris, France.
Platform of Transfer in Cancer Biology, Georges François Leclerc Cancer -UNICANCER, Dijon, France.
Genomic and Immunotherapy Medical Institute, Dijon, France.

Rebeca Piñeiro-Sabarís (R)

Intercellular Signaling in Cardiovascular Development & Disease Laboratory, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Ciber de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.

Aline Verstraeten (A)

Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.
Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.

Hatem Elif Kamber Kaya (HE)

Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts.
Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts.

Marcos Siguero-Álvarez (M)

Intercellular Signaling in Cardiovascular Development & Disease Laboratory, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Ciber de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.

Guillaume Goudot (G)

Université Paris Cité, INSERM, U970 PARCC, Paris, France.
Vascular Medicine Department, Assistance Publique-Hȏpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
French Research Consortium RHU STOP-AS, Rouen, France.

Donal MacGrogan (D)

Intercellular Signaling in Cardiovascular Development & Disease Laboratory, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Ciber de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.

Ilse Luyckx (I)

Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.
Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.

Shoshana Shpitzen (S)

Cardiology Department, Hadassah Medical Center, Jerusalem, Israel.
Faculty of Medicine, the Hebrew University, Jerusalem, Israel.
Braun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Galina Levin (G)

Cardiology Department, Hadassah Medical Center, Jerusalem, Israel.
Faculty of Medicine, the Hebrew University, Jerusalem, Israel.
Braun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Guy Kelman (G)

Faculty of Medicine, the Hebrew University, Jerusalem, Israel.
The Jerusalem Center for Personalized Computational Medicine, Jerusalem, Israel.

Noga Reshef (N)

Faculty of Medicine, the Hebrew University, Jerusalem, Israel.
The Jerusalem Center for Personalized Computational Medicine, Jerusalem, Israel.

Hugo Mananet (H)

Platform of Transfer in Cancer Biology, Georges François Leclerc Cancer -UNICANCER, Dijon, France.
Genomic and Immunotherapy Medical Institute, Dijon, France.

Jake Holdcraft (J)

Department of Anesthesiology, Boston University School of Medicine, Boston, Massachusetts.

Jochen D Muehlschlegel (JD)

Department of Anesthesiology, Boston University School of Medicine, Boston, Massachusetts.

Gina M Peloso (GM)

Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.

Olya Oppenheim (O)

School of Neurobiology, Biochemistry and Biophysics, George S. Wise Faculty of Life Science, Tel Aviv University, Tel Aviv, Israel.

Charles Cheng (C)

Université Paris Cité, INSERM, U970 PARCC, Paris, France.
Vascular Medicine Department, Assistance Publique-Hȏpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
French Research Consortium RHU STOP-AS, Rouen, France.

Jean-Michael Mazzella (JM)

Université Paris Cité, INSERM, U970 PARCC, Paris, France.
Vascular Medicine Department, Assistance Publique-Hȏpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.

Gregor Andelfinger (G)

Cardiovascular Genetics, Department of Pediatrics, CHU Sainte-Justine, Université de Montreal, Montreal, Quebec, Canada.

Seema Mital (S)

Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

Per Eriksson (P)

Cardiovascular Medicine Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Solna, Sweden.

Clarisse Billon (C)

Genetics Department, Assistance Publique-Hȏpitaux de Paris, Hôpital Européen Georges Pompidou, National Referral Center for Rare Vascular Diseases, VASCERN MSA European Reference Center, Paris, France.
Université Paris Cité, INSERM, U970 PARCC, Paris, France.

Mahyar Heydarpour (M)

Department of Medicine, Division of Endocrinology, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Harry C Dietz (HC)

McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Xavier Jeunemaitre (X)

Université Paris Cité, INSERM, U970 PARCC, Paris, France.
Vascular Medicine Department, Assistance Publique-Hȏpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.

Eran Leitersdorf (E)

Cardiology Department, Hadassah Medical Center, Jerusalem, Israel.
Faculty of Medicine, the Hebrew University, Jerusalem, Israel.
Braun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

David Sprinzak (D)

School of Neurobiology, Biochemistry and Biophysics, George S. Wise Faculty of Life Science, Tel Aviv University, Tel Aviv, Israel.

Stephen C Blacklow (SC)

Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts.
Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts.

Simon C Body (SC)

Department of Anesthesiology, Boston University School of Medicine, Boston, Massachusetts.

Shai Carmi (S)

Braun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Bart Loeys (B)

Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.
Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.

José Luis de la Pompa (JL)

Intercellular Signaling in Cardiovascular Development & Disease Laboratory, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Ciber de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.

Dan Gilon (D)

Cardiology Department, Hadassah Medical Center, Jerusalem, Israel.

Emmanuel Messas (E)

Université Paris Cité, INSERM, U970 PARCC, Paris, France.
Vascular Medicine Department, Assistance Publique-Hȏpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
French Research Consortium RHU STOP-AS, Rouen, France.

Ronen Durst (R)

Cardiology Department, Hadassah Medical Center, Jerusalem, Israel.
Faculty of Medicine, the Hebrew University, Jerusalem, Israel.
Braun School of Public Health and Community Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH